Abstract
Increasing interest in cytochrome P450 2B6 (CYP2B6) genetic polymorphism was stimulated by revelations of a specific CYP2B6 genotype significantly affecting the metabolism of various drugs in common clinical use in terms of increasing drug efficacy and avoiding adverse drug reactions. The present study aimed to determine the frequencies of CYP2B6*4 CYP2B6*5, CYP2B6*6, CYP2B6*7 and CYP2B6*9 alleles in healthy Turkish individuals (n = 172). Frequencies of three single nucleotide polymorphisms were 516G>T (28 %), 785A>G (33 %), and 1459C>T (12 %). The frequencies of CYP2B6*1, *4, *5, *6, *7, and *9 alleles were 54.3 (95 % CI 49.04–59.56), 6.4 % (95 % CI 3.81–8.99), 11 % (95 % CI 7.69–14.31), 25.3 % (95 % CI 20.71–29.89), 0.87 % (95 % CI −0.11–1.85) and 2.0 % (95 % CI 0.52–3.48), respectively. Allele *6 was more frequent (25.3 %) than the other variant alleles in Turkish subjects. The frequencies of CYP2B6*4, *5, *6, *7, and *9 alleles were similar to European populations but significantly different from that reported for Asian populations. This is the first study to document the frequencies of the CYP2B6*4, *5, *6, *7, *9 alleles in the healthy Turkish individuals and our results could provide clinically useful information on drug metabolism by CYP2B6 in Turkish population.
Similar content being viewed by others
References
Hodgson E, Rose RL (2007) The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. Pharmacol Ther 113:420–428
Ekins S, Wrighton SA (1999) The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31:719–754
Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V et al (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306
Wang H, Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598–610
Zanger UM, Hofmann MH (2008) Polymorphic cytochromes P450 CYP2B6 and CYP2D6: recent advances on single nucleotide polymorphisms affecting splicing. Acta Chim Slov 5:38–44
Yamazaki H, Inoue K, Hashimoto M, Shimada T (1999) Roles of CYP2A6 and CYP2B6 in nicotine coxidation by human liver microsomes. Arch Toxicol 73:65–70
Kreth K, Kovar K, Schwab M, Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of ‘ecstasy’-related designer drugs. Biochem Pharmacol 59:1563–1571
Hesse L, Venkatakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI et al (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–1183
Coller JK, Kregsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T et al (2002) The influence of CYP2B6, CYP2C9, and CYP2D6 genotypes on the formation of the antiestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157–167
Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L et al (2002) Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12:627–634
Hesse L, He P, Krishnaswamy S, Hao Q, Hogan K, von Molteke LL et al (2004) Pharmacogenetic determinations of interindividual variability in bupropion hydroxylation by cytochrome P4502B6 in human liver microsomes. Pharmacokinetics 14:225–238
Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML et al (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906–922
Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U et al (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399–415
Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M et al (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311:34–43
Guengerich FP (1995) Human cytochrome P450 enzymes. In: Ortiz de Montellano PR (ed) Cytochrome P450. Plenum, New York, pp 473–535
Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW et al (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42
Yamano S, Nhamburo PT, Aoyama T, Meyer UA, Inaba T, Kalow W, Gelboin HV, McBride OW, Gonzalez F (1989) cDNA cloning and sequence and cDNAdirected expression of human P450IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28:7340–7348
Zukunft J, Lang T, Richter T, Hirsch-Ernst KI, Nussler AK, Klein K et al (2005) A natural CYP2B6 TATA box polymorphism (−82T→C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 67:1772–1782
Klein K, Lang T, Saussele T et al (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861–873
Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N et al (2003) Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398–403
Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM et al (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391–2400
Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V (2005) Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 40:1358–1361
Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL et al (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV infected patients. Pharmacogenet Genomics 15:1–5
Hasse B, Gunthard HF, Bleiber G, Krause M (2005) Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 40:e22–e23
Suzen HS, Yuce N, Guven G, Duydu Y, Erke T (2005) TYMS and DPYD polymorphisms in a Turkish population. Eur J Clin Pharmacol 61:881–885
Suzen HS, Gucyener E, Sakalli O, Uckun Z, Kose G, Ustel D, Duydu Y (2010) CAT C-262T and GPX1 Pro198Leu polymorphisms in a Turkish population. Mol Biol Rep 37:87–92
Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985–993
Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF (2003) Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122–132
Sueyoshi T, Negishi M (2001) Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 41:123–143
Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C et al (2004) Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 32:348–358
Rae JM, Soukhova NV, Flockhart DA, Desta Z (2002) Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30:525–530
Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M et al (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189–197
Desta Z, Saussele T, Ward B et al (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547–558
Kirchheiner J, Klein C, Meineke I et al (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619–626
Chung JY, Jang SB, Lee YJ, Park MS, Park K (2011) Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 51:53–59
Guan S, Huang M, Chan E, Chen X, Duan W, Zhou SF (2006) Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur J Pharm Sci 29:14–21
Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y et al (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417–421
Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, Oka S (2009) Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. Drug Metab Dispos 37:1991–1993
Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA (2006) Prevalence of CYP2B6 alleles in malariaendemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 62:267–275
Arenaz I, Vicente J, Fanlo A, Vasquez P, Medina JC, Conde B, Gonzalez-Andrade F, Sinues B (2010) Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans. Fundam Clin Pharmacol 24:247–253
Rotger M, Tegude H, Colombo S et al (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 81:557–566
Jacob RM, Johnstone EC, Neville MJ, Walton RT (2004) Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin Chem 50:1372–1377
Ellison CA, Abou El-Ella SS, Tawfik M, Lein PJ, Olson JR (2012) Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. J Toxicol Environ Health A 75:232–241
Restrepo JG, Martinez C, Garcıa-Agundez A, Gaviria E, Laguna JJ, Elena Garcıa-Martın E, Agundez JAG (2011) Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet Genomics 21:773–778
Acknowledgments
This work was supported, in part, by The Scientific and Technological Research Council of Turkey under Project 109S147.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yuce-Artun, N., Kose, G. & Suzen, H.S. Allele and genotype frequencies of CYP2B6 in a Turkish population. Mol Biol Rep 41, 3891–3896 (2014). https://doi.org/10.1007/s11033-014-3256-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-014-3256-9